198 related articles for article (PubMed ID: 30653362)
1. Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma.
Intile JL; Rassnick KM; Al-Sarraf R; Chretin JD
J Am Anim Hosp Assoc; 2019; 55(2):101-109. PubMed ID: 30653362
[TBL] [Abstract][Full Text] [Related]
2. Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs.
Flory AB; Rassnick KM; Al-Sarraf R; Bailey DB; Balkman CE; Kiselow MA; Autio K
J Vet Intern Med; 2008; 22(1):164-71. PubMed ID: 18289305
[TBL] [Abstract][Full Text] [Related]
3. Dacarbazine as single-agent therapy for relapsed lymphoma in dogs.
Griessmayr PC; Payne SE; Winter JE; Barber LG; Shofer FS
J Vet Intern Med; 2009; 23(6):1227-31. PubMed ID: 19709354
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a multidrug chemotherapy protocol with mitoxantrone based maintenance (CHOP-MA) for the treatment of canine lymphoma.
Daters AT; Mauldin GE; Mauldin GN; Brodsky EM; Post GS
Vet Comp Oncol; 2010 Mar; 8(1):11-22. PubMed ID: 20230577
[TBL] [Abstract][Full Text] [Related]
5. Treatment of relapsed canine lymphoma with doxorubicin and dacarbazine.
Van Vechten M; Helfand SC; Jeglum KA
J Vet Intern Med; 1990; 4(4):187-91. PubMed ID: 2401965
[TBL] [Abstract][Full Text] [Related]
6. Comparison of efficacy and toxicity of doxorubicin and mitoxantrone in combination chemotherapy for canine lymphoma.
Wang SL; Lee JJ; Liao AT
Can Vet J; 2016 Mar; 57(3):271-6. PubMed ID: 26933263
[TBL] [Abstract][Full Text] [Related]
7. Substitution of mitoxantrone for doxorubicin in a multidrug chemotherapeutic protocol for first-line treatment of dogs with multicentric intermediate- to large-cell lymphoma.
Marquardt TM; Lindley SES; Smith AN; Cannon CM; Rodriguez CO; Thamm DH; Childress MO; Northrup NC
J Am Vet Med Assoc; 2019 Jan; 254(2):236-242. PubMed ID: 30605381
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.
Moore AS; Ogilvie GK; Ruslander D; Rand WS; Cotter SM; Getzy DM; L'Heureux DA; Dennis RA
J Am Vet Med Assoc; 1994 Jun; 204(12):1903-5. PubMed ID: 8077132
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of temozolomide or dacarbazine in combination with an anthracycline for rescue chemotherapy in dogs with lymphoma.
Dervisis NG; Dominguez PA; Sarbu L; Newman RG; Cadile CD; Swanson CN; Kitchell BE
J Am Vet Med Assoc; 2007 Aug; 231(4):563-9. PubMed ID: 17696856
[TBL] [Abstract][Full Text] [Related]
10. Thirteen-week dose-intensifying simultaneous combination chemotherapy protocol for malignant lymphoma in dogs.
Zenker I; Meichner K; Steinle K; Kessler M; Hirschberger J
Vet Rec; 2010 Nov; 167(19):744-8. PubMed ID: 21257510
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and toxicity of carboplatin and cytarabine chemotherapy for dogs with relapsed or refractory lymphoma (2000-2013).
Gillem J; Giuffrida M; Krick E
Vet Comp Oncol; 2017 Jun; 15(2):400-410. PubMed ID: 26463827
[TBL] [Abstract][Full Text] [Related]
12. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of factors associated with second remission in dogs with lymphoma undergoing retreatment with a cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy protocol: 95 cases (2000-2007).
Flory AB; Rassnick KM; Erb HN; Garrett LD; Northrup NC; Selting KA; Phillips BS; Locke JE; Chretin JD
J Am Vet Med Assoc; 2011 Feb; 238(4):501-6. PubMed ID: 21320021
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
15. Correlation Between Body Weight and Mitoxantrone-Associated Neutropenia in Dogs.
Richardson D; Poirier VJ; Matsuyama A; Calvalido J
J Am Anim Hosp Assoc; 2018; 54(3):144-149. PubMed ID: 29558218
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of single-agent mitoxantrone as chemotherapy for relapsing canine lymphoma.
Lucroy MD; Phillips BS; Kraegel SA; Simonson ER; Madewell BR
J Vet Intern Med; 1998; 12(5):325-9. PubMed ID: 9773407
[TBL] [Abstract][Full Text] [Related]
17. Influence of asparaginase on a combination chemotherapy protocol for canine multicentric lymphoma.
Jeffreys AB; Knapp DW; Carlton WW; Thomas RM; Bonney PL; Degortari A; Lucroy MD
J Am Anim Hosp Assoc; 2005; 41(4):221-6. PubMed ID: 15995158
[TBL] [Abstract][Full Text] [Related]
18. Treatment of dogs with lymphoma using a 12-week, maintenance-free combination chemotherapy protocol.
Simon D; Nolte I; Eberle N; Abbrederis N; Killich M; Hirschberger J
J Vet Intern Med; 2006; 20(4):948-54. PubMed ID: 16955821
[TBL] [Abstract][Full Text] [Related]
19. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma.
Northrup NC; Rassnick KM; Snyder LA; Stone MS; Kristal O; Cotter SM; Moore AS
J Vet Intern Med; 2002; 16(5):570-5. PubMed ID: 12322708
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy-induced neutropenia is associated with prolonged remission duration and survival time in canine lymphoma.
Wang SL; Lee JJ; Liao AT
Vet J; 2015 Jul; 205(1):69-73. PubMed ID: 26004824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
